Macrolide resistance and its impacts on M. pneumoniae pneumonia in children: Comparison of two recent epidemics in Korea

Jong Hyun Kim, Jee Yong Kim, Chang Hoon Yoo, Won Hee Seo, Young Yoo, Dae-Jin Song, Ji-Tae Choung

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The aim of this study was to investigate the change in macrolide resistance rate in pediatric Mycoplasma pneumoniae pneumonia and to evaluate the influence of macrolide-resistant M. pneumoniae (MRMP) on the clinical course of disease, by comparing 2 recent, consecutive epidemics in Korea. Methods: A total of 250 patients with M. pneumoniae pneumonia admitted to a single tertiary hospital were enrolled in this study. Detection of MRMP was based on specific point mutations in domain V of the 23S rRNA gene. The medical records of enrolled patients were reviewed retrospectively, and the clinical courses and laboratory data were compared. Results: The macrolide resistance rate of M. pneumoniae was 51.1% (48/94) in the 2011 epidemic, and 87.2% (136/156) in the 2015 epidemic. All MRMP isolates had the A2063G point mutation. In comparison of 2 epidemics, the mean age of patients with M. pneumoniae pneumonia was increased, and the total febrile days and febrile days after initiation of macrolides were prolonged in the 2015 epidemic. Overall severity of MRMP or macrolide-susceptible M. pneumoniae (MSMP) pneumonia over 2 epidemics was not significantly changed. However, the proportion of patients who had a fever lasting more than 72 hours after initiation of macrolides and who received corticosteroid treatment were higher in MRMP pneumonia during 2 epidemics. Conclusions: The macrolide resistance rate of M. pneumoniae has risen rapidly over 2 recent, consecutive epidemics, and this has been associated with a prolonged clinical course and increased use of corticosteroids to treat pediatric M. pneumoniae pneumonia.

Original languageEnglish
Pages (from-to)340-346
Number of pages7
JournalAllergy, Asthma and Immunology Research
Volume9
Issue number4
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Mycoplasma pneumoniae
Macrolides
Korea
Pneumonia
Mycoplasma Pneumonia
Fever
Point Mutation
Adrenal Cortex Hormones
Pediatrics
rRNA Genes
Tertiary Care Centers
Medical Records

Keywords

  • Drug resistance
  • Macrolides
  • Mycoplasma pneumoniae

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

Macrolide resistance and its impacts on M. pneumoniae pneumonia in children : Comparison of two recent epidemics in Korea. / Kim, Jong Hyun; Kim, Jee Yong; Yoo, Chang Hoon; Seo, Won Hee; Yoo, Young; Song, Dae-Jin; Choung, Ji-Tae.

In: Allergy, Asthma and Immunology Research, Vol. 9, No. 4, 01.01.2017, p. 340-346.

Research output: Contribution to journalArticle

@article{b68024b383bc4f85b5865a46135160cd,
title = "Macrolide resistance and its impacts on M. pneumoniae pneumonia in children: Comparison of two recent epidemics in Korea",
abstract = "Purpose: The aim of this study was to investigate the change in macrolide resistance rate in pediatric Mycoplasma pneumoniae pneumonia and to evaluate the influence of macrolide-resistant M. pneumoniae (MRMP) on the clinical course of disease, by comparing 2 recent, consecutive epidemics in Korea. Methods: A total of 250 patients with M. pneumoniae pneumonia admitted to a single tertiary hospital were enrolled in this study. Detection of MRMP was based on specific point mutations in domain V of the 23S rRNA gene. The medical records of enrolled patients were reviewed retrospectively, and the clinical courses and laboratory data were compared. Results: The macrolide resistance rate of M. pneumoniae was 51.1{\%} (48/94) in the 2011 epidemic, and 87.2{\%} (136/156) in the 2015 epidemic. All MRMP isolates had the A2063G point mutation. In comparison of 2 epidemics, the mean age of patients with M. pneumoniae pneumonia was increased, and the total febrile days and febrile days after initiation of macrolides were prolonged in the 2015 epidemic. Overall severity of MRMP or macrolide-susceptible M. pneumoniae (MSMP) pneumonia over 2 epidemics was not significantly changed. However, the proportion of patients who had a fever lasting more than 72 hours after initiation of macrolides and who received corticosteroid treatment were higher in MRMP pneumonia during 2 epidemics. Conclusions: The macrolide resistance rate of M. pneumoniae has risen rapidly over 2 recent, consecutive epidemics, and this has been associated with a prolonged clinical course and increased use of corticosteroids to treat pediatric M. pneumoniae pneumonia.",
keywords = "Drug resistance, Macrolides, Mycoplasma pneumoniae",
author = "Kim, {Jong Hyun} and Kim, {Jee Yong} and Yoo, {Chang Hoon} and Seo, {Won Hee} and Young Yoo and Dae-Jin Song and Ji-Tae Choung",
year = "2017",
month = "1",
day = "1",
doi = "10.4168/aair.2017.9.4.340",
language = "English",
volume = "9",
pages = "340--346",
journal = "Allergy, Asthma and Immunology Research",
issn = "2092-7355",
publisher = "Korean Academy of Asthma, Allergy and Clinical Immunology",
number = "4",

}

TY - JOUR

T1 - Macrolide resistance and its impacts on M. pneumoniae pneumonia in children

T2 - Comparison of two recent epidemics in Korea

AU - Kim, Jong Hyun

AU - Kim, Jee Yong

AU - Yoo, Chang Hoon

AU - Seo, Won Hee

AU - Yoo, Young

AU - Song, Dae-Jin

AU - Choung, Ji-Tae

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: The aim of this study was to investigate the change in macrolide resistance rate in pediatric Mycoplasma pneumoniae pneumonia and to evaluate the influence of macrolide-resistant M. pneumoniae (MRMP) on the clinical course of disease, by comparing 2 recent, consecutive epidemics in Korea. Methods: A total of 250 patients with M. pneumoniae pneumonia admitted to a single tertiary hospital were enrolled in this study. Detection of MRMP was based on specific point mutations in domain V of the 23S rRNA gene. The medical records of enrolled patients were reviewed retrospectively, and the clinical courses and laboratory data were compared. Results: The macrolide resistance rate of M. pneumoniae was 51.1% (48/94) in the 2011 epidemic, and 87.2% (136/156) in the 2015 epidemic. All MRMP isolates had the A2063G point mutation. In comparison of 2 epidemics, the mean age of patients with M. pneumoniae pneumonia was increased, and the total febrile days and febrile days after initiation of macrolides were prolonged in the 2015 epidemic. Overall severity of MRMP or macrolide-susceptible M. pneumoniae (MSMP) pneumonia over 2 epidemics was not significantly changed. However, the proportion of patients who had a fever lasting more than 72 hours after initiation of macrolides and who received corticosteroid treatment were higher in MRMP pneumonia during 2 epidemics. Conclusions: The macrolide resistance rate of M. pneumoniae has risen rapidly over 2 recent, consecutive epidemics, and this has been associated with a prolonged clinical course and increased use of corticosteroids to treat pediatric M. pneumoniae pneumonia.

AB - Purpose: The aim of this study was to investigate the change in macrolide resistance rate in pediatric Mycoplasma pneumoniae pneumonia and to evaluate the influence of macrolide-resistant M. pneumoniae (MRMP) on the clinical course of disease, by comparing 2 recent, consecutive epidemics in Korea. Methods: A total of 250 patients with M. pneumoniae pneumonia admitted to a single tertiary hospital were enrolled in this study. Detection of MRMP was based on specific point mutations in domain V of the 23S rRNA gene. The medical records of enrolled patients were reviewed retrospectively, and the clinical courses and laboratory data were compared. Results: The macrolide resistance rate of M. pneumoniae was 51.1% (48/94) in the 2011 epidemic, and 87.2% (136/156) in the 2015 epidemic. All MRMP isolates had the A2063G point mutation. In comparison of 2 epidemics, the mean age of patients with M. pneumoniae pneumonia was increased, and the total febrile days and febrile days after initiation of macrolides were prolonged in the 2015 epidemic. Overall severity of MRMP or macrolide-susceptible M. pneumoniae (MSMP) pneumonia over 2 epidemics was not significantly changed. However, the proportion of patients who had a fever lasting more than 72 hours after initiation of macrolides and who received corticosteroid treatment were higher in MRMP pneumonia during 2 epidemics. Conclusions: The macrolide resistance rate of M. pneumoniae has risen rapidly over 2 recent, consecutive epidemics, and this has been associated with a prolonged clinical course and increased use of corticosteroids to treat pediatric M. pneumoniae pneumonia.

KW - Drug resistance

KW - Macrolides

KW - Mycoplasma pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=85019209285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019209285&partnerID=8YFLogxK

U2 - 10.4168/aair.2017.9.4.340

DO - 10.4168/aair.2017.9.4.340

M3 - Article

AN - SCOPUS:85019209285

VL - 9

SP - 340

EP - 346

JO - Allergy, Asthma and Immunology Research

JF - Allergy, Asthma and Immunology Research

SN - 2092-7355

IS - 4

ER -